<DOC>
	<DOCNO>NCT00234104</DOCNO>
	<brief_summary>This drug develop treat cardiac edema . The primary purpose study investigate dose response body weight seven-day repeated oral administration OPC-41061 15 , 30 , 45 mg placebo patient extracellular volume expansion secondary CHF despite take furosemide 40 mg/d . This study conduct Japan .</brief_summary>
	<brief_title>A Dose-finding Study OPC-41061 Treatment Cardiac Edema ( Congestive Heart Failure )</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>1 . Patients CHF exhibit edema , jugular venous distention , hepatomegaly , pulmonary congestion , 3rd sound due extracellular volume expansion 2 . Hospitalized patient patient hospitalize study commencement observation period endofstudy examination 3 . Men woman age 20 80 ( noninclusive ) time give consent 4 . Patients take furosemide 40 mg/d ( oral dosing ) without alteration dosage 3 day observation period 5 . Patients whose body weight stable ( ±1.0 kg ) 2 day prior commencement study drug administration 1 . Patients unstable heart failure ( acute heart failure , acute exacerbation chronic heart failure , etc ) 2 . Patients implant ventricular assist device 3 . Patients undergone schedule undergo follow procedure Heart surgery involve thoracotomy within 60 day prior screen examination Pacemaker implant surgery involve bilateral pacing within 60 day prior screen examination Angioplasty , electrophysiologic device implantation , ventricular assist device implantation , heart transplant , cardiac surgery schedule within 30 day screen examination 4 . Patients follow disease , complication , symptom Suspected hypovolemia Onset acute myocardial infarction within 30 day prior screen examination Hypertrophic cardiomyopathy ( exclude diastolic phase ) Definitively diagnose active myocarditis amyloid cardiomyopathy Valvular heart disease significant stenosis Untreated thyroid disease Progressive neurological disease ( Alzheimer 's disease , Parkinson 's disease , multiple sclerosis , etc ) severe episodic neurological disease ( epilepsy , GuillainBarre syndrome , etc ) Diabetes poor glycemic control Anuria Hepatic coma Hyponatremia moderate great severity ( serum Na &lt; 120 mEq/L ) 5 . Patients history follow condition Occurrence sustain ventricular tachycardia ventricular fibrillation within 30 day prior screen examination ( except patient use implantable cardioverterdefibrillator ) Evident cerebral infarction Multiple stroke Occurrence cerebrovascular accident within 30 day prior screen examination Hypersensitivity idiosyncratic reaction benzazepine derivative , benazapril 6 . Patients history drug abuse alcoholism past year 7 . Patients state morbid obesity body mass index ( weight [ kg ] ÷ height [ ] 2 ) 35 8 . Patients supine systolic arterial blood pressure le 90 mmHg 9 . Patients follow abnormal laboratory value : Hemoglobin &lt; 9 g/dL , total bilirubin &gt; 3.0 mg/dL , serum creatine &gt; 3.0 mg/dL , serum Na &gt; 147 mEq/L , serum K &gt; 5.5 mEq/L 10 . Patients capable take oral medication 11 . Patients nurse , pregnant , capable pregnancy , intend become pregnant shortly study period 12 . Patients take study drug OPC41061 within 30 day prior screen 13 . Patients previously take OPC41061 study another study OPC41061 14 . Patients otherwise judge principal investigator attend investigator inappropriate inclusion study ( eg , patient hepatic cirrhosis , renal disease , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>OPC-41061</keyword>
	<keyword>Tolvaptan</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>Edema</keyword>
	<keyword>Extracellular volume expansion</keyword>
</DOC>